Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BIOT Biotech Acquisition	$10.15 -0.8%	$10.15	$8.30 ▼ $10.41	$291.81M	-0.12	244,605 shs	44,400 shs
OCUL Ocular Therapeutix	$8.00 -1.7%	$7.36	$4.79 ▼ $11.78	$1.28B	1.51	1.40 million shs	423,169 shs
OPTN OptiNose	$9.60	$9.30	$4.82 ▼ $20.03	$97.22M	-0.88	63,216 shs	N/A
TRLPF Acerus Pharmaceuticals	$0.22	$0.22	$0.08 ▼ $0.34	$56.90M	2.6	5,474 shs	N/A

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BIOT Biotech Acquisition	0.00%	0.00%	0.00%	0.00%	0.00%
OCUL Ocular Therapeutix	+3.17%	+12.74%	-0.85%	+14.01%	+38.67%
OPTN OptiNose	0.00%	0.00%	+3.00%	+65.23%	-40.19%
TRLPF Acerus Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	3.6553 of 5 stars	3.4	1.0	0.0	4.1	2.6	2.5	0.0
OPTN OptiNose	3.1858 of 5 stars	1.0	5.0	0.0	4.2	2.4	2.5	0.6
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BIOT Biotech Acquisition	0.00	N/A	N/A	N/A
OCUL Ocular Therapeutix	2.88	Moderate Buy	$16.25	103.05% Upside
OPTN OptiNose	2.00	Hold	$9.00	-6.25% Downside
TRLPF Acerus Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TRLPF, OCUL, OPTN, and BIOT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/29/2025	OCUL Ocular Therapeutix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
5/19/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$9.00 ➝ $9.00
5/6/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $14.00
4/8/2025	OCUL Ocular Therapeutix	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
4/8/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/21/2025	OPTN OptiNose	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$15.00 ➝ $9.00
3/21/2025	OPTN OptiNose	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$18.00 ➝ $9.00
3/20/2025	OPTN OptiNose	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
3/20/2025	OPTN OptiNose	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$17.00 ➝ $9.00
3/18/2025	OCUL Ocular Therapeutix	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$17.00
3/11/2025	OCUL Ocular Therapeutix	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$15.00

(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	($0.95) per share	N/A
OCUL Ocular Therapeutix	$59.65M	21.37	N/A	N/A	$0.79 per share	10.13
OPTN OptiNose	$81.86M	1.19	N/A	N/A	($11.56) per share	-0.83
TRLPF Acerus Pharmaceuticals	$7.38M	7.71	N/A	N/A	N/A	∞

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BIOT Biotech Acquisition	-$6.86M	N/A	0.00	∞	N/A	N/A	-42.22%	3.48%	N/A
OCUL Ocular Therapeutix	-$80.74M	-$1.15	N/A	N/A	N/A	-283.74%	-45.18%	-30.87%	8/6/2025 (Estimated)
OPTN OptiNose	-$35.48M	-$3.00	N/A	N/A	N/A	-41.16%	N/A	-27.42%	8/6/2025 (Estimated)
TRLPF Acerus Pharmaceuticals	-$18.79M	-$0.08	N/A	∞	N/A	-254.66%	-346.72%	-94.54%	N/A

Latest TRLPF, OCUL, OPTN, and BIOT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	OPTN OptiNose	-$0.74	-$1.01	-$0.27	-$1.92	$17.70 million	$18.51 million
3/26/2025	Q4 2024	OPTN OptiNose	-$0.70	-$0.03	+$0.67	-$0.03	$21.02 million	$21.47 million
3/3/2025	Q4 2024	OCUL Ocular Therapeutix	-$0.24	-$0.29	-$0.05	-$0.29	$16.89 million	$17.08 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BIOT Biotech Acquisition	N/A	N/A	N/A	N/A	N/A
OCUL Ocular Therapeutix	N/A	N/A	N/A	N/A	N/A
OPTN OptiNose	N/A	N/A	N/A	N/A	N/A
TRLPF Acerus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BIOT Biotech Acquisition	N/A	0.03	0.03
OCUL Ocular Therapeutix	0.19	13.01	12.94
OPTN OptiNose	N/A	0.79	0.72
TRLPF Acerus Pharmaceuticals	0.64	1.35	0.90

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BIOT Biotech Acquisition	80.01%
OCUL Ocular Therapeutix	59.21%
OPTN OptiNose	85.60%
TRLPF Acerus Pharmaceuticals	0.02%

Insider Ownership

Company	Insider Ownership
BIOT Biotech Acquisition	19.00%
OCUL Ocular Therapeutix	2.30%
OPTN OptiNose	2.30%
TRLPF Acerus Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BIOT Biotech Acquisition	4	28.75 million	23.29 million	Not Optionable
OCUL Ocular Therapeutix	230	159.30 million	151.71 million	Optionable
OPTN OptiNose	190	10.13 million	9.83 million	Not Optionable
TRLPF Acerus Pharmaceuticals	29	258.62 million	N/A	Not Optionable

TRLPF, OCUL, OPTN, and BIOT Headlines

Recent News About These Companies

Takeda Pharmaceutical Co. Ltd. ADR

February 8, 2024 | wsj.com

Other OTC Pharmaceuticals - Lithuania

September 17, 2023 | statista.com

2023 A Big Year For Testosterone: AbbVie And ANI Pharmaceuticals Best Positioned To Benefit

January 1, 2023 | seekingalpha.com

Acerus Reports Second Quarter 2022 Financial Results

August 9, 2022 | financialpost.com

Acerus Reports Fourth Quarter and Full Year 2021 Financial Results

March 15, 2022 | financialpost.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TRLPF, OCUL, OPTN, and BIOT Company Descriptions

Biotech Acquisition NASDAQ:BIOT

Biotech Acquisition Company does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, reorganization, or other business combination with one or more businesses. The company was incorporated in 2020 and is based in New York, New York.

Ocular Therapeutix NASDAQ:OCUL

$8.00 -0.14 (-1.68%)

As of 12:17 PM Eastern

Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.

OptiNose NASDAQ:OPTN

$9.60 0.00 (0.00%)

As of 05/21/2025

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.

Acerus Pharmaceuticals OTCMKTS:TRLPF

$0.22 0.00 (0.00%)

As of 07/21/2023

Acerus Pharmaceuticals Corporation, a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and distribution of pharmaceutical products for men's and women's health. The company offers Natesto, a nasal gel for testosterone replacement therapy in adult males diagnosed with hypogonadism; Estrace, an oral tablet for the symptomatic relief of menopausal symptoms; and UriVarx, a natural health product that helps reduce symptoms of hyperactive bladder, such as daytime urinary frequency, urgency, and nocturia. It also engages in developing Lidbree, a short acting lidocaine formulation delivered through a proprietary device into the vaginal mucosal tissue; Stendra, a PDE5 inhibitor for the treatment of erectile dysfunction; Elegant vaginal moisturizer, which provides comfort to women suffering from vaginal dryness; and Elegant pH, a pH balanced vaginal product; Gynoflor, an ultra-low dose vaginal estrogen combined with a probiotic for the treatment of vaginal atrophy, restoration of vaginal flora, and treatment of certain vaginal infections; and Tefina, a clinical stage product for women with female sexual dysfunction. Acerus Pharmaceuticals Corporation sells products through its salesforce in Canada; and through a network of licensed distributors in the United States and internationally. The company was formerly known as Trimel Pharmaceuticals Corporation and changed its name to Acerus Pharmaceuticals Corporation in September 2015. Acerus Pharmaceuticals Corporation was founded in 2008 and is headquartered in Mississauga, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time